There is a 'valley of death' in European research and innovation, says CEO of Novo Nordisk Foundation ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

IMMvention retained rights to use its technology to potentially pursue other targets, such as Parkinson’s or Alzheimer’s ...

Birmingham is suing drug manufacturers and health companies, alleging they worked together to establish an “insulin pricing scheme” and inflate the cost of life-saving medicine.

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. In June 2021, Novo Nordisk won ...

Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held March ...